Skip to content
Menu

LivaNova PLC LIVN

Full chart Compare
Set alert

Price alert · LIVN

All alert types
90.73 USD -1.34 (-1.46%)

Regular-session close

90.73 0.00 0.00%

After hours · Nov 20, 4:26 PM ET

90.15 Day range 93.16
53.48 52-week range 99.38
YTD
+47.46%
1 year
+69.84%

5D +0.21 (+0.23%)

9294MonTueWedThuFri91.21
Market cap
5.00B
Revenue (ttm)
1.51B
Profit margin
13.01%
EPS (ttm)
3.49
Shares out
55.09M
P/E ratio
26.00
Forward P/E
19.18
YTD return
+47.46%
1-year return
+69.84%
50-day average
81.35
Volume
499.88K
Avg volume
688.45K
Open
91.61
Previous close
92.07
Day's range
90.15 – 93.16
52-week range
53.48 – 99.38
Beta
0.92
Analysts
Buy
Price target
105.09 (+15.8%)
Earnings date
Feb 24, 2027

Key statistics

200-day average
74.72
Enterprise value
4.87B
PEG ratio
0.93
Price / sales
3.32
Price / book
3.64
Revenue growth
9.90%
Free cash flow
67.71M
Total cash
563.47M
Total debt
357.07M
Return on equity
15.50%
Short % of float
13.26%

Fundamental scorecard

12 of 25 checks passed on LIVN’s reported financials

ValueGrowthProfitabilityHealthDividend

12of 25 checks passed

  • Value 0 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
LIVN Revenue — quarterly 393.15M
LIVN Net income — quarterly 34.29M
LIVN EPS — quarterly 0.62

Earnings

LIVN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20260.98———
Nov 4, 2026Sep 30, 20261.061.23+0.17+16.04%
Aug 5, 2026Jun 30, 20261.091.26+0.17+15.60%
May 6, 2026Mar 31, 20260.850.98+0.13+15.29%
Feb 25, 2026Dec 31, 20250.800.86+0.06+7.50%
Nov 5, 2025Sep 30, 20250.9191.11+0.19+20.78%

Upgrades / downgrades

LIVN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026BarclaysmainOverweightOverweight
Nov 5, 2026BairdmainOutperformOutperform
Nov 4, 2026NeedhammainBuyBuy
Oct 7, 2026Barclaysinit—Overweight
Sep 2, 2026Piper SandlerreitOverweightOverweight
Aug 5, 2026NeedhammainBuyBuy

About LivaNova PLC

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.

Sector
Healthcare
Industry
Medical Devices
Country
United Kingdom
Website
livanova.com

News

Your note

Sign in to keep a note on LIVN — it syncs with the Stock Master app.

Insider holders

LIVN insider holders
InsiderRelationLatest transactionDateShares held
BARRY JAMES CHRISTOPHERDirectorConversion of Exercise of derivative securityJun 14, 20267,918
BOLTON STEPHANIEOfficerConversion of Exercise of derivative securityMar 29, 202622,189
ENXING SENG STACYDirectorConversion of Exercise of derivative securityJun 14, 202615,307
KOZY WILLIAM ADirectorConversion of Exercise of derivative securityJun 14, 202637,566
MAKATSARIA VLADIMIR A.Chief Executive OfficerConversion of Exercise of derivative securityMar 29, 202614,167
O'KANE SHARONDirectorConversion of Exercise of derivative securityJun 12, 202511,304

Institution ownership

LIVN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.14.05%7,739,664702.22MSep 29, 2026
Primecap Management Company7.60%4,187,158379.90MSep 29, 2026
FMR, LLC7.22%3,976,650360.80MSep 29, 2026
Invesco Ltd.5.29%2,914,016264.39MSep 29, 2026
Hood River Capital Management LLC4.66%2,568,241233.02MSep 29, 2026
State Street Corporation3.93%2,166,157196.54MSep 29, 2026

Fund ownership

LIVN fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%1,963,642178.16MSep 29, 2026
VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund3.45%1,902,700172.63MJun 29, 2026
AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund3.05%1,679,556152.39MJul 30, 2026
American Century ETF Trust-Avantis U.S. Small Cap Value ETF2.92%1,607,363145.84MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.63%1,450,682131.62MSep 29, 2026
Artisan Partners Funds Inc.-Artisan International Small-Mid Fund2.50%1,374,576124.72MJun 29, 2026